Cometriq (Cabozantinib) For Medullary Thyroid Cancer Approved By FDA

Cometriq (cabozantinib) has been approved by the FDA for the treatment of progressive medullary thyroid cancer that has metastasized - spread to other parts of the body. Medullary thyroid cancer, a rare form of thyroid cancer, starts off in the cells that make calcitonin, a hormone which regulates calcium levels in the blood and bones...



Cancer-Medicine in USA